galactomannan has been researched along with Leukemia* in 13 studies
4 review(s) available for galactomannan and Leukemia
Article | Year |
---|---|
ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients.
As culture-based methods for the diagnosis of invasive fungal diseases (IFD) in leukemia and hematopoietic SCT patients have limited performance, non-culture methods are increasingly being used. The third European Conference on Infections in Leukemia (ECIL-3) meeting aimed at establishing evidence-based recommendations for the use of biological tests in adult patients, based on the grading system of the Infectious Diseases Society of America. The following biomarkers were investigated as screening tests: galactomannan (GM) for invasive aspergillosis (IA); β-glucan (BG) for invasive candidiasis (IC) and IA; Cryptococcus Ag for cryptococcosis; mannan (Mn) Ag/anti-mannan (A-Mn) Ab for IC, and PCR for IA. Testing for GM, Cryptococcus Ag and BG are included in the revised EORTC/MSG (European Organization for Research and Treatment of Cancer/Mycoses Study Group) consensus definitions for IFD. Strong evidence supports the use of GM in serum (A II), and Cryptococcus Ag in serum and cerebrospinal fluid (CSF) (A II). Evidence is moderate for BG detection in serum (B II), and the combined Mn/A-Mn testing in serum for hepatosplenic candidiasis (B III) and candidemia (C II). No recommendations were formulated for the use of PCR owing to a lack of standardization and clinical validation. Clinical utility of these markers for the early management of IFD should be further assessed in prospective randomized interventional studies. Topics: Antigens, Fungal; beta-Glucans; Biomarkers; Congresses as Topic; European Union; Galactose; Hematopoietic Stem Cell Transplantation; Leukemia; Mannans; Mycoses; Transplantation, Homologous | 2012 |
[Diagnosis of Aspergillus infections in hematology and oncology].
Topics: Antigens, Fungal; Aspergillosis; Aspergillus; beta-Glucans; Breath Tests; DNA, Fungal; Early Diagnosis; Galactose; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Leukemia; Lung; Mannans; Neutropenia; Organ Transplantation; Transplantation Immunology | 2012 |
Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation?
Invasive fungal infections (IFIs) are difficult to diagnose, especially early in the course of infection when antifungal therapy is most effective. There are two commercially available biomarker assays useful for detection of the IFIs most commonly seen in patients with hematologic malignancies, the galactomannan and beta glucan assays. The former is specific for aspergillosis, the latter positive for not only Aspergillus and Candida species, but several other clinically relevant fungal pathogens as well. Both have good assay performance characteristics, provide rapid test results, are widely available, can be assayed non-invasively, and are positive early in the course of infection, often before onset of signs and symptoms of infection. Adoption of these assays into clinical practice has led to reduced need to perform invasive procedures to obtain deep tissue to establish the diagnosis of invasive fungal infections. Improved survival rates from aspergillosis are, in part, due to earlier detection of infection and earlier therapy. Topics: Acute Disease; Aspergillosis; Aspergillus; beta-Glucans; Biomarkers; Candida; Candidiasis; Galactose; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mannans; Transplantation, Homologous | 2012 |
New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients.
Recognition and treatment of invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients are important clinical challenges. New diagnostic tools, such as fungal serologic assays and high-resolution CT scans, offer the hope for earlier initiation of antifungal therapy and improved treatment results. New antifungal agents offer choices that in some cases are less toxic than older drugs and in other cases are more efficacious. Combining the new diagnostic tools with new drugs, novel strategies are being evaluated to change our approaches to these deadly infections. Topics: Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Galactose; Glucans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mannans | 2007 |
2 trial(s) available for galactomannan and Leukemia
Article | Year |
---|---|
Serum galactomannan screening for diagnosis of invasive pulmonary aspergillosis in children after stem cell transplantation or with high-risk leukemia.
Both transplanted and leukemia patients are at high risk (HR) for invasive pulmonary aspergillosis (IPA). Methods for rapid diagnosis are crucial. Our objective was to investigate the impact of serial serum galactomannan assay (GMA) screening on IPA diagnosis in children. Between January 2010 and December 2011, all children following stem cell transplantation (SCT) or with HR leukemia were prospectively included. Serum samples for GMA were taken once-twice weekly. Results >.5 were considered positive. Patients suspected of having IPA were stratified as possible, probable, and definite. Forty-six children (median age, 8 years) were included, 38 after SCT (32 allogeneic), 8 with HR leukemia. A total of 510 samples were taken; screening period was 1-6 months for 34 patients. GMA was negative in 28 patients, all but one without suspicion of IPA. Eighteen patients had positive GMA: while four (22%) were upgraded to probable IPA, fourteen (78%) were considered as false positives (FP), some associated with piperacillin-tazobactam treatment. GMA sensitivity and specificity were 0.8 and 0.66, respectively; positive- and negative-predictive values (PPV, NPV) were 0.22 and 0.96, respectively. GMA may have a role in evaluating HR children for IPA. Both NPV and FP rates are high. The cost benefit of early detection versus over-diagnosis should be further studied. Topics: Adolescent; Adult; Allografts; Autografts; Child; Child, Preschool; Female; Galactose; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Invasive Pulmonary Aspergillosis; Leukemia; Male; Mannans; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam | 2015 |
Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients.
The double sandwich ELISA detecting Aspergillus galactomannan (GM) was prospectively evaluated for the diagnosis of invasive aspergillosis (IA) in 50 haematological patients at risk for IA. Serum samples were collected once weekly as long as the risk factors persisted. Six patients had proven or probable IA (3 A. fumigatus, 1 A. flavus, 1 A. niger, 1 A. ustus) and the GM titres were parallel to the clinical evolution of IA. Six of nine patients with suspected IA had at least two consecutive serum GM titres above 1 ng/ml and died with increasing titres, whereas the GM-negative patients survived. Positive GM titres did not anticipate the isolation of fungi. Unfortunately, positive GM titres did not anticipate the initiation of antifungal therapy, based on clinical suspicion. Moreover, if a true-positive result was defined as two consecutive positive serum samples, four patients out of 35 without proven, probable or suspected IA were positive. Then, the rate of false-positive results was high (12%) in the range previously reported. Nevertheless, the GM ELISA appears useful to assess IA and to follow the efficacy of antifungal treatment. Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antigens, Fungal; Aspergillosis; Aspergillus; Bone Marrow Transplantation; Child; Enzyme-Linked Immunosorbent Assay; False Positive Reactions; Fatal Outcome; Female; Galactose; Humans; Leukemia; Male; Mannans; Middle Aged; Neutropenia; Prospective Studies | 1997 |
7 other study(ies) available for galactomannan and Leukemia
Article | Year |
---|---|
The screening of blood by Aspergillus PCR and galactomannan ELISA precedes BAL detection in patients with proven and probable IA.
Early detection of Aspergillus infection has the potential to facilitate a more effective management of invasive disease. Data from probable/proven cases of invasive aspergillosis (IA) with a positive galactomannan enzyme-linked immunosorbent assay (GM) bronchoalveolar lavage fluid (BALF) was analyzed in respect to serum GM and/or polymerase chain reaction (PCR) screening of blood samples prior to, or concurrent with bronchoscopy. Concurrent serum GM testing is less sensitive than BALF itself. Nevertheless screening of blood using GM or PCR testing detected IA cases earlier (GM: 42% or PCR: 56%), particularly when combined (GM/PCR: 73%). Therefore, regular screening facilitates and improves early detection of IA in patients suffering from acute leukemia. Topics: Adolescent; Adult; Aged; Aspergillus; Bronchoalveolar Lavage Fluid; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Female; Galactose; Humans; Invasive Pulmonary Aspergillosis; Leukemia; Male; Mannans; Middle Aged; Polymerase Chain Reaction; Young Adult | 2020 |
Adherence to, and outcomes of, a galactomannan screening protocol in high-risk hematology patients.
A twice-weekly galactomannan (gm) screening protocol was implemented in high-risk hematology inpatients. Study objectives were to determine adherence to the protocol, use of selected resources, and patient outcomes.. This retrospective cohort study compared outcomes of interest before and after implementation of gm screening. Adults undergoing matched related allogeneic hematopoietic stem-cell transplantation or induction chemotherapy for acute leukemia were eligible. Patients could be enrolled more than once and were evaluated as episodes. Adherence to the gm protocol was assessed in post-implementation episodes. Use of broad-spectrum antifungals (bsafs), consultations (infectious diseases, respirology), and diagnostic procedures (computed tomography imaging, bronchoalveolar lavage) were compared between phases, as were the patient outcomes of all-cause mortality and clinical success (alive and not taking a bsaf).. Of 182 episodes consecutively screened, 70 per phase were enrolled. Clinical characteristics and duration of assessment were similar for the phases. Full or partial adherence to the protocol was observed in 61 post-implementation episodes (87%), with full adherence in 40 episodes (57%). More episodes in the pre-implementation phase than in the post-implementation phase involved receipt of bsafs, consultations, and diagnostics (27% vs. 7%,. Implementation of a gm screening protocol was feasible and associated with significantly fewer episodes involving receipt of bsafs and consultations, and with significantly more episodes showing clinical success. Topics: Adult; Aged; Antifungal Agents; Biomarkers; Feasibility Studies; Female; Galactose; Guideline Adherence; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Leukemia; Male; Mannans; Mass Screening; Middle Aged; Mycoses; Neutropenia; Opportunistic Infections; Practice Guidelines as Topic; Retrospective Studies; Treatment Outcome | 2018 |
Cross-recognition of aspergillus galactomannan caused by Listeria monocytogenes infection.
We report a case of Listeria monocytogenes bacteremia in a leukemic patient having a positive assay for aspergillus galactomannan (GM), although no evidence of aspergillosis was found. Supernatant obtained from L. monocytogenes strain suspension was reactive with GM-assay. L. monocytogenes produces a soluble antigen that is cross-reactive with Aspergillus GM. Topics: Anti-Bacterial Agents; Antifungal Agents; Antigens, Fungal; Antineoplastic Agents; Aspergillosis; Aspergillus; Bacteremia; Cross Reactions; Galactose; Humans; Leukemia; Listeria monocytogenes; Male; Mannans; Middle Aged | 2013 |
Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005-2009.
To evaluate risk factors, diagnostic procedures, and treatment outcomes of invasive aspergillosis (IA) in patients with hematological malignancies.. A retrospective analysis of data from proven/probable IA cases that occurred from 2005 to 2009 at 10 hematology centers was performed.. We identified 176 IA cases that mainly occurred in patients with acute leukemias (58.5%), mostly those on induction/re-induction treatments (39.8%). Prolonged neutropenia was the most frequent risk factor for IA (61.4%). The lungs were the most frequently affected site (93.8%) and computed tomography detected abnormalities in all episodes; however, only 53.7% of patients had findings suggestive of IA. Galactomannan (GM) detection in serum or bronchoalveolar lavage fluid (positive in 79.1% and 78.8% of episodes, respectively) played a crucial role in IA diagnosis. Neutrophil count and antifungal prophylaxis did not influence the GM positivity rate, but empirical therapy decreased this rate (in serum). Of the IA cases, 53.2% responded to initial antifungal therapy. The combination of voriconazole and echinocandin, even as initial or salvage therapy, did not perform better than voriconazole monotherapy (p=0.924 for initial therapy and p=0.205 for salvage therapy). Neutrophil recovery had a significant role in the response to initial (but not salvage) antifungal therapy.. Our retrospective analysis identified key diagnostic and treatment characteristics, and this understanding could improve the management of hematological malignancy patients with IA. Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Bronchoalveolar Lavage Fluid; Child; Child, Preschool; Czech Republic; Databases, Factual; Echinocandins; Female; Galactose; Humans; Leukemia; Lung Diseases, Fungal; Male; Mannans; Middle Aged; Neutrophils; Pyrimidines; Retrospective Studies; Slovakia; Triazoles; Voriconazole; Young Adult | 2013 |
Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients.
Invasive aspergillosis (IA) remains an important cause of mortality in acute leukaemia patients. Previous studies reported that serum galactomannan (GM) levels correlate strongly with IA outcomes in patients with haematological cancers. This study aimed to clarify the usefulness of serial GM testing for outcome evaluation of IA in acute leukaemia patients. We retrospectively analysed 58 acute leukaemia patients who had IA during neutropenic period after chemotherapy and whose serum GM was serially monitored until discharge or death. The kappa correlation coefficient was used to determine the strength of correlation between GM and clinical outcome (survival or death) of IA. The correlation between clinical outcome and GM kinetics was good at week 6 [κ = 0.663, 95% confidence interval (CI): 0.465-0.861] and excellent at week 12 (κ = 0.819, 95% CI: 0.667-0.91). Survival was significantly better in patients whose GM values normalised than in patients with persistently positive GM (P < 0.0001) regardless of whether neutropenia resolved or acute leukaemia responded to chemotherapy. In neutropenic patients with acute leukaemia, serum GM correlated strongly with survival outcome of IA. This finding further supports the usefulness of the GM index as a surrogate marker for assessing IA outcome and the need for serial GM testing in therapeutic monitoring. Topics: Adolescent; Adult; Aged; Clinical Laboratory Techniques; Female; Galactose; Humans; Invasive Pulmonary Aspergillosis; Leukemia; Male; Mannans; Middle Aged; Retrospective Studies; Serum; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy.
Persistent or recurrent fevers of unknown origin (PFUO) in neutropenic patients on broad-spectrum antibiotics have traditionally been treated with empirical antifungal therapy (EAFT). The lack of survival benefit seen with the use of amphotericin B deoxycholate (AmB-D) as EAFT has been attributed to its toxicities. More recently, newer, less toxic and more expensive antifungal agents such as the lipid formulations of AmB, the newer azoles (fluconazole, itraconazole and voriconazole) and caspofungin have been analysed in a number of EAFT trials. Compared with AmB-D the newer agents have superior safety but are of equivalent efficacy. This lack of survival advantage is related to the fact that the trigger for commencement of EAFT is late and non-specific. Thus, alternative approaches are required. New sensitive serological and molecular tests for the detection of Aspergillus antigens and genomic DNA have been developed and evaluated in accuracy studies. These tests have been incorporated into management strategies (i.e. pre-emptive strategies) to direct antifungal therapy. The pre-emptive approach has been shown to be safe and feasible but its impact on clinically important patient outcomes such as survival is less clear. Other advances include the introduction of effective, non-toxic mould-active antifungal prophylaxis and patient risk-group stratification. In this paper we provide new evidence-based algorithms for the diagnosis and treatment of PFUO in adult patients undergoing stem cell transplantation and chemotherapy for haematological malignancy which incorporate these newer diagnostic tests and are directed by the risk category of the patient and type of antifungal prophylaxis the patient is receiving. Topics: Adult; Algorithms; Antifungal Agents; Antigens, Fungal; Aspergillus; beta-Glucans; Evidence-Based Medicine; Fever of Unknown Origin; Galactose; Humans; Leukemia; Mannans; Polymerase Chain Reaction; Recurrence; Stem Cell Transplantation; Tomography, X-Ray Computed | 2008 |
Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies.
The performance of a sandwich enzyme-linked immunosorbent assay (ELISA) which detects Aspergillus galactomannan (GM) was evaluated in bronchoalveolar lavage (BAL) fluid samples from 19 patients who were treated for hematological malignancies and who were suspected of having invasive pulmonary aspergillosis (IPA). All patients had fever and pulmonary infiltrates on the chest roentgenogram on the day that the BAL fluid was obtained. The ELISA results were compared with the results of culture and Aspergillus genus-specific PCR analysis of BAL fluid samples. ELISA was also performed with serum samples. Aspergillus species were detected by PCR or ELISA with BAL fluid samples from five of seven patients who had radiological evidence of IPA. Serum ELISA results were positive for all patients with ELISA-positive BAL fluid, and for four patients the serum ELISA was positive before the BAL fluid was obtained. PCR and ELISA were positive for 2 and 1 of 10 BAL fluid samples, respectively, obtained from patients without radiological evidence of IPA, and 5 and 2 of 35 BAL fluid samples, respectively, obtained from nonneutropenic patients. This preliminary investigation suggests that GM may be detected by ELISA in BAL fluid samples from patients at risk of IPA, but that monitoring of serum GM levels may allow for the earlier diagnosis of IPA. However, further evaluation in prospective studies is required. Topics: Adult; Aged; Antigens, Fungal; Aspergillosis; Aspergillus; Bronchoalveolar Lavage Fluid; Enzyme-Linked Immunosorbent Assay; Evaluation Studies as Topic; Female; Galactose; Hematologic Diseases; Humans; Leukemia; Lung Diseases, Fungal; Lymphoma; Male; Mannans; Middle Aged; Polymerase Chain Reaction; Sensitivity and Specificity | 1995 |